Ultra Violette recalled 49,275 tubes of its Velvet Screen SPF 50 sunscreen on August 22, 2025. Testing revealed SPF levels inconsistent with the label, posing a serious risk. Consumers should stop using the product immediately.
Subpotent/Super-potent Product: Testing of the SPF 50 sunscreen revealed inconsistency in SPF results ranging from SPF 4, 10, 21, 26, 33, 60, 61, and 64.
Consumers and healthcare providers should stop using this product immediately. Contact GRACE & FIRE PTY LTD or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled products include 15 mL tubes (NDC 84803-106-01, UPC 9355909006068) and 50 mL tubes (NDC 84803-106-02, UPC 9355909005924). These products were distributed by Grace & Fire USA Inc. nationwide in the USA.
Testing revealed SPF results ranging from SPF 4 to SPF 64, which may not provide adequate sun protection. This inconsistency poses a high risk of sunburn and skin damage.
No specific incidents have been reported related to this recall. However, the potential for skin damage due to inadequate SPF levels is significant.
Consumers should stop using the recalled sunscreen immediately. Contact Grace & Fire Pty Ltd or a healthcare provider for guidance on safe alternatives.
For further information, consumers can visit the FDA website or contact Grace & Fire Pty Ltd directly.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.